Next Article in Journal
The Dose–Response Association between Nitrogen Dioxide Exposure and Serum Interleukin-6 Concentrations
Previous Article in Journal
Imipramine Protects against Bone Loss by Inhibition of Osteoblast-Derived Microvesicles
Article Menu
Issue 5 (May) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2017, 18(5), 1016;

Impaired Platelet Aggregation and Rebalanced Hemostasis in Patients with Chronic Hepatitis C Virus Infection

Department of Infectious Diseases, University Hospital of Copenhagen, Rigshospitalet, 2100 København, Denmark
Department of Hepatology, University Hospital of Copenhagen, Rigshospitalet, 2100 København, Denmark
Department of Clinical Immunology, University Hospital of Copenhagen, Rigshospitalet, 2100 København, Denmark
Author to whom correspondence should be addressed.
Academic Editor: Akihiro Tamori
Received: 3 March 2017 / Revised: 3 May 2017 / Accepted: 4 May 2017 / Published: 8 May 2017
(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
Full-Text   |   PDF [773 KB, uploaded 8 May 2017]   |  


Increased risk of both cardiovascular disease (CVD) and bleeding has been found in patients with chronic hepatitis C (CHC) infection, and a re-balanced hemostasis has been proposed. The aim of this study was to investigate functional whole blood coagulation and platelet function in CHC infection. The prospective study included 82 patients with CHC infection (39 with advanced liver fibrosis and 43 with no or mild liver fibrosis) and 39 healthy controls. A total of 33 patients were treated for CHC infection and achieved sustained virological response (SVR). Baseline and post-treatment blood samples were collected. Hemostasis was assessed by both standard coagulation tests and functional whole blood hemostatic assays (thromboelastograhy (TEG), and platelet aggregation (Multiplate). Patients with CHC and advanced fibrosis had impaired platelet aggregation both compared to patients with no or mild fibrosis and to healthy controls. Patients with CHC and advanced fibrosis also had lower antithrombin, platelet count, and coagulation factors II-VII-X compared to healthy controls. In contrast, TEG did not differ between groups. In treated patients achieving SVR, post-treatment platelet count was higher than pre-treatment counts (p = 0.033) and ADPtest, ASPItest, and RISTOhightest all increased post treatment (all p < 0.05). All Multiplate tests values, however, remained below those in the healthy controls. CHC-infected patients displayed evidence of rebalanced hemostasis with only partly hemostatic normalization in patients achieving SVR. The implications of rebalanced hemostasis and especially the impact on risk of CVD and bleeding warrants further studies. View Full-Text
Keywords: HCV; hemostasis; platelet aggregation HCV; hemostasis; platelet aggregation

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Nielsen, N.S.; Jespersen, S.; Gaardbo, J.C.; Arnbjerg, C.J.; Clausen, M.R.; Kjær, M.; Gerstoft, J.; Ballegaard, V.; Ostrowski, S.R.; Nielsen, S.D. Impaired Platelet Aggregation and Rebalanced Hemostasis in Patients with Chronic Hepatitis C Virus Infection. Int. J. Mol. Sci. 2017, 18, 1016.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top